Role of mast cells in colorectal cancer development, the jury is still out

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 1, 2012, Pages 9-13

  Heijmans, J ^a   Buller N V ^a   Muncan, V ^a   van den Brink, G R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adaptive immune system; Colon cancer; Innate immune system; Mast cell

Indexed keywords

APC PROTEIN; AZOXYMETHANE; CIMETIDINE; GLUTATHIONE TRANSFERASE; HISTAMINE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ADAPTIVE IMMUNITY; ALLELE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COLON ADENOMA; COLON CARCINOGENESIS; COLON CARCINOMA; COLORECTAL CANCER; CROHN DISEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE DURATION; DISEASE MODEL; EPITHELIUM CELL; ERYTHROPOIESIS; GENE MUTATION; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; INTESTINE POLYP; LAMINA PROPRIA; LEUKOCYTE; MACROPHAGE; MAST CELL; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; ADENOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; MAST CELLS;

EID: 82955184624     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.001     Document Type: Review

References (47)

1. Adams W.J., Morris D.L. Short-course cimetidine and survival with colorectal cancer. Lancet 1994, 344:1768-1769.
2. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
3. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-884.
4. Cecchini M.G., Dominguez M.G., Mocci S., Wetterwald A., Felix R., Fleisch H., Chisholm O., Hofstetter W., Pollard J.W., Stanley E.R. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development 1994, 120:1357-1372.
5. Chabot B., Stephenson D.A., Chapman V.M., Besmer P., Bernstein A. The proto-oncogene c-Kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988, 335:88-89.
6. Chappaz S., Gartner C., Rodewald H.R., Finke D. Kit ligand and Il7 differentially regulate Peyer's patch and lymph node development. J. Immunol. 2010, 185:3514-3519.
7. Chapple K.S., Cartwright E.J., Hawcroft G., Tisbury A., Bonifer C., Scott N., Windsor A.C., Guillou P.J., Markham A.F., Coletta P.L., Hull M.A. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol. 2000, 156:545-553.
8. Diks S.H., Hardwick J.C., Diab R.M., van Santen M.M., Versteeg H.H., Van Deventer S.J., Richel D.J., Peppelenbosch M.P. Activation of the canonical beta-catenin pathway by histamine. J. Biol. Chem. 2003, 278:52491-52496.
9. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
10. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
11. Ekbom A., Helmick C., Zack M., Adami H.O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990, 336:357-359.
12. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990, 323:1228-1233.
13. Geissler E.N., Ryan M.A., Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-Kit proto-oncogene. Cell 1988, 55:185-192.
14. Gounaris E., Erdman S.E., Restaino C., Gurish M.F., Friend D.S., Gounari F., Lee D.M., Zhang G., Glickman J.N., Shin K., Rao V.P., Poutahidis T., Weissleder R., McNagny K.M., Khazaie K. Mast cells are an essential hematopoietic component for polyp development. Proc. Natl. Acad. Sci. U. S. A 2007, 104:19977-19982.
15. Hardwick J.C., Van Den Brink G.R., Offerhaus G.J., Van Deventer S.J., Peppelenbosch M.P. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001, 20:819-827.
16. Hull M.A., Booth J.K., Tisbury A., Scott N., Bonifer C., Markham A.F., Coletta P.L. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer 1999, 79:1399-1405.
17. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., Bronson R.T., Mahmood U., Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U. S. A 2010, 107:1565-1570.
18. Itzkowitz S.H., Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004, 126:1634-1648.
19. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-G17.
20. Ivanova A., Signore M., Caro N., Greene N.D., Copp A.J., Martinez-Barbera J.P. In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. Genesis 2005, 43:129-135.
21. Jass J.R. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 1986, 39:585-589.
22. + T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
23. Kelly M.D., King J., Cherian M., Dwerryhouse S.J., Finlay I.G., Adams W.J., King D.W., Lubowski D.Z., Morris D.L. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer 1999, 85:1658-1663.
24. Kitamura Y., Go S., Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978, 52:447-452.
25. Laky K., Lefrancois L., Puddington L. Age-dependent intestinal lymphoproliferative disorder due to stem cell factor receptor deficiency: parameters in small and large intestine. J. Immunol. 1997, 158:1417-1427.
26. Lee S.H., Hu L.L., Gonzalez-Navajas J., Seo G.S., Shen C., Brick J., Herdman S., Varki N., Corr M., Lee J., Raz E. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat. Med. 2010, 16:665-670.
27. Leulier F., Lemaitre B. Toll-like receptors-taking an evolutionary approach. Nat. Rev. Genet. 2008, 9:165-178.
28. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
29. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995, 346:115.
30. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247:322-324.
31. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
32. Musch W., Wege A.K., Mannel D.N., Hehlgans T. Generation and characterization of alpha-chymase-Cre transgenic mice. Genesis 2008, 46:163-166.
33. Neufert C., Becker C., Neurath M.F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007, 2:1998-2004.
34. Nielsen H.J., Hansen U., Christensen I.J., Reimert C.M., Brunner N., Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J. Pathol. 1999, 189:487-495.
35. Puddington L., Olson S., Lefrancois L. Interactions between stem cell factor and c-Kit are required for intestinal immune system homeostasis. Immunity 1994, 1:733-739.
36. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
37. Regula J., Rupinski M., Kraszewska E., Polkowski M., Pachlewski J., Orlowska J., Nowacki M.P., Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 2006, 355:1863-1872.
38. Ritchie K.J., Walsh S., Sansom O.J., Henderson C.J., Wolf C.R. Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi. Proc. Natl. Acad. Sci. U. S. A 2009, 106:20859-20864.
39. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
40. Sinnamon M.J., Carter K.J., Sims L.P., Lafleur B., Fingleton B., Matrisian L.M. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008, 29:880-886.
41. Sint N.J. J. de, V, E.W. Steyerberg, E.J. Kuipers, M.E. van Leerdam, and S.J. Veldhuyzen-van Zanten, Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am. J. Transplant. 2010, 10:868-876.
42. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183:534-536.
43. Svennevig J.L., Lunde O.C., Holter J., Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br. J. Cancer 1984, 49:375-377.
44. Wedemeyer J., Galli S.J. Decreased susceptibility of mast cell-deficient Kit(W)/Kit(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab. Invest. 2005, 85:388-396.
45. Wershil B.K., Mast I.X. Cell-deficient mice and intestinal biology. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278:G343-G348.
46. Wiktor-Jedrzejczak W.W., Ahmed A., Szczylik C., Skelly R.R. Hematological characterization of congenital osteopetrosis in op/op mouse. J. Exp. Med. 1982, 156:1516-1527.
47. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L., Hsu R.Y., Birkett N.C., Okino K.H., Murdock D.C. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-Kit tyrosine kinase receptor. Cell 1990, 63:213-224.